title: Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.
abstract: This review describes the preclinical mechanisms that may underlie the increased therapeutic benefit of combination therapy-with the N-methyl-D-aspartate receptor antagonist, memantine, and an acetylcholinesterase inhibitor (AChEI)-for the treatment of Alzheimer's disease (AD). Memantine, and the AChEIs target two different aspects of AD pathology. Both drug types have shown significant efficacy as monotherapies for the treatment of AD. Furthermore, clinical observations indicate that their complementary mechanisms offer superior benefit as combination therapy. Based on the available literature, the authors have considered the preclinical mechanisms that could underlie such a combined approach. Memantine addresses dysfunction in glutamatergic transmission, while the AChEIs serve to increase pathologically lowered levels of the neurotransmitter acetylcholine. In addition, preclinical studies have shown that memantine has neuroprotective effects, acting to prevent glutamatergic over-stimulation and the resulting neurotoxicity. Interrelations between the glutamatergic and cholinergic pathways in regions of the brain that control learning and memory mean that combination treatment has the potential for a complex influence on disease pathology. Moreover, studies in animal models have shown that the combined use of memantine and the AChEIs can produce greater improvements in measures of memory than either treatment alone. As an effective approach in the clinical setting, combination therapy with memantine and an AChEI has been a welcome advance for the treatment of patients with AD. Preclinical data have shown how these drugs act via two different, but interconnected, pathological pathways, and that their complementary activity may produce greater effects than either drug individually.
authors: In Vitro Pharmacology, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318, Frankfurt, Germany. christopher.parsons@merz.de
authors: Chris G
authors: CG
authors: Parsons
authors: Wojciech
authors: W
authors: Danysz
authors: Andrzej
authors: A
authors: Dekundy
authors: Irena
authors: I
authors: Pulte
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage; D006801:Humans; D008559:Memantine / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D008559:Memantine
references: Behav Brain Res. 2011 Aug 10;221(2):505-14
references: 21130117
references: Behav Pharmacol. 2006 Sep;17(5-6):411-24
references: 16940762
references: Am J Geriatr Psychiatry. 2006 May;14(5):428-37
references: 16670247
references: Eur J Pharmacol. 1992 Sep 4;219(3):451-4
references: 1425971
references: Neurology. 2001 Aug 28;57(4):613-20
references: 11524468
references: Neurology. 2006 Jul 11;67(1):57-63
references: 16832078
references: Brain Res. 2005 Nov 16;1062(1-2):120-6
references: 16248989
references: J Neurophysiol. 2004 Aug;92(2):1216-25
references: 15044519
references: Eur J Neurol. 2010 Oct;17(10):1236-48
references: 20831773
references: Brain Res. 2002 Dec 20;958(1):210-21
references: 12468047
references: J Neurosci. 1994 Mar;14(3 Pt 1):1358-65
references: 8120631
references: N Engl J Med. 2003 Apr 3;348(14):1333-41
references: 12672860
references: J Comp Neurol. 1990 Dec 22;302(4):824-52
references: 1982006
references: Alzheimers Res Ther. 2011 Jul 20;3(4):23
references: 21774798
references: Synapse. 2001 Mar 1;39(3):201-12
references: 11169769
references: Neurology. 1977 Aug;27(8):783-90
references: 560649
references: Neuropharmacology. 2004 Sep;47(3):408-13
references: 15275830
references: Neurotox Res. 2000;2(2-3):85-97
references: 16787834
references: Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):255-62
references: 17132970
references: Expert Opin Pharmacother. 2010 Jul;11(10):1765-71
references: 20540654
references: Am J Pathol. 2010 Feb;176(2):870-80
references: 20042680
references: J Clin Pharmacol. 2005 May;45(5):519-28
references: 15831775
references: Trends Neurosci. 1999 Jun;22(6):273-80
references: 10354606
references: Clin Drug Investig. 2008;28(6):361-74
references: 18479178
references: Pharmacol Rev. 1999 Mar;51(1):7-61
references: 10049997
references: Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):263-8
references: 17132971
references: J Neurochem. 1983 Feb;40(2):503-9
references: 6822833
references: J Neurosci. 2006 Feb 1;26(5):1588-95
references: 16452682
references: Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):125-30
references: 18525283
references: Neuroscience. 2001;105(2):277-85
references: 11672595
references: JAMA. 2004 Jan 21;291(3):317-24
references: 14734594
references: Sci Signal. 2009 Oct 20;2(93):re8
references: 19843960
references: Neurobiol Aging. 1989 Sep-Oct;10(5):593-602
references: 2554168
references: Int J Geriatr Psychiatry. 2005 May;20(5):459-64
references: 15852444
references: Curr Med Res Opin. 2007 May;23(5):1187-97
references: 17519086
references: J Mol Neurosci. 2006;30(1-2):227-32
references: 17192682
references: Neuropharmacology. 1999 Jan;38(1):85-108
references: 10193901
references: Psychopharmacology (Berl). 1977 May 9;52(3):283-9
references: 406632
references: Neurology. 1992 Apr;42(4):733-8
references: 1314341
references: Mol Neurobiol. 2008 Aug;38(1):101-21
references: 18690555
references: J Neurosci. 1992 Nov;12(11):4427-36
references: 1432103
references: Drug News Perspect. 1998 Nov;11(9):523-69
references: 15616669
references: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593
references: 16437532
references: Neurosci Lett. 2001 Mar 16;300(3):157-60
references: 11226635
references: Life Sci. 2000 Feb 11;66(12):1079-83
references: 10737358
references: Brain Res. 1994 Aug 29;655(1-2):7-11
references: 7812791
references: Int J Clin Pract. 2006 Jan;60(1):110-8
references: 16409439
references: Behav Brain Res. 2011 Aug 10;221(2):594-603
references: 20553766
references: N Engl J Med. 1985 Jul 4;313(1):7-11
references: 2582256
references: J Biol Chem. 2010 Dec 17;285(51):40180-91
references: 20947502
references: Curr Alzheimer Res. 2008 Feb;5(1):83-9
references: 18288936
references: J Clin Psychiatry. 2008 Mar;69(3):341-8
references: 18294023
references: Drugs Aging. 2004;21(7):453-78
references: 15132713
references: Ann N Y Acad Sci. 1993 Sep 24;695:42-5
references: 8239310
references: J Alzheimers Dis. 2012;30(2):245-51
references: 22414570
references: FASEB J. 1990 Jul;4(10):2745-52
references: 2165009
references: Dement Geriatr Cogn Disord. 2007;24(1):20-7
references: 17496417
references: Neuropharmacology. 2007 Nov;53(6):699-723
references: 17904591
references: Eur J Pharmacol. 1995 Oct 6;293(3):267-70
references: 8666045
references: Biol Psychiatry. 1997 Jan 15;41(2):135-44
references: 9018383
references: Dement Geriatr Cogn Disord. 2007;24(2):111-7
references: 17622714
references: Int Clin Psychopharmacol. 2003 Mar;18(2):81-5
references: 12598818
references: Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S1-5
references: 12973744
references: Prog Brain Res. 1998;116:331-47
references: 9932386
references: J Neurochem. 1995 Nov;65(5):2165-9
references: 7595503
references: Brain Res Bull. 1982 Jun;8(6):727-49
references: 6182962
references: Neuropharmacology. 1999 Sep;38(9):1253-9
references: 10471078
references: Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):209-21
references: 18580597
references: Trends Neurosci. 1993 Oct;16(10):409-14
references: 7504356
references: J Neurochem. 1996 Jul;67(1):310-6
references: 8667007
references: Dement Geriatr Cogn Disord. 2007;24(2):138-45
references: 17622761
references: Neuroscience. 2004;123(3):785-92
references: 14706791
references: Ann Pharmacother. 2004 Sep;38(9):1389-94
references: 15266045
references: Drugs Aging. 2011 Jul 1;28(7):539-46
references: 21721598
references: Jpn J Pharmacol. 2002 Feb;88(2):223-6
references: 11928725
references: Neuroreport. 1995 Nov 27;6(17):2409-13
references: 8747164
references: J Biol Chem. 2007 Apr 13;282(15):11590-601
references: 17308309
references: J Neurochem. 1996 Jul;67(1):277-86
references: 8667003
references: Neuropharmacology. 1993 Dec;32(12):1337-50
references: 8152525
references: Pharmacol Biochem Behav. 1979 Feb;10(2):205-10
references: 450929
references: Prog Neurobiol. 2002 Oct;68(3):209-45
references: 12450488
references: Brain. 1984 Mar;107 ( Pt 1):253-74
references: 6538106
references: Neuropharmacology. 1999 Jun;38(6):735-67
references: 10465680
references: Exp Brain Res. 2000 Sep;134(1):58-65
references: 11026726
references: Int J Geriatr Psychiatry. 1999 Jan;14(1):3-47
references: 10029935
references: Biol Psychiatry. 2001 Feb 1;49(3):200-10
references: 11230871
references: J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600-7
references: 19204022
references: Alzheimers Res Ther. 2013 Jan 21;5(1):6
references: 23336974
references: Br Med J. 1978 Nov 25;2(6150):1457-9
references: 719462
references: Neuroscience. 2000;99(1):17-23
references: 10924948
references: Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32
references: 12973747
references: Neurobiol Aging. 2011 Apr;32(4):614-23
references: 19446369
references: Neuropharmacology. 1997 Jul;36(7):961-71
references: 9257940
references: Behav Neurosci. 2004 Feb;118(1):223-36
references: 14979800
references: J Pharmacol Exp Ther. 2003 Sep;306(3):821-7
references: 12805474
references: Prog Brain Res. 1989;79:335-43
references: 2685904
references: Eur J Pharmacol. 1996 Jan 18;296(1):1-8
references: 8720470
references: J Neurosci. 2007 Jan 24;27(4):796-807
references: 17251419
references: Alzheimers Dement. 2011 Nov;7(6):579-92
references: 22055975
references: N Engl J Med. 2012 Mar 8;366(10):893-903
references: 22397651
references: Neuroscience. 1999;92(4):1465-74
references: 10426500
references: Br J Pharmacol. 2004 Feb;141(4):644-52
references: 14744806
references: J Neurochem. 1993 May;60(5):1589-604
references: 8473885
references: Can J Psychiatry. 2011 Oct;56(10):596-604
references: 22014692